IFRX: SEC Form 6-K filed by InflaRx N.V.
Stocks in this Quantisnow insightHealth Care
Historical context for IFRX
Across the 19 sessions after earlier IFRX headlines, the stock closed higher 12 times and lower 6 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IFRX | SPY |
|---|---|---|---|
| May 6, 2026 | InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Sharesand 1 other headline that session | +26.9% | +1.4% |
| May 4, 2026 | InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes | +1.4% | -0.4% |
| May 1, 2026 | InflaRx to Report First Quarter 2026 Results on May 7, 2026 | +1.4% | +0.3% |
| Apr 28, 2026 | InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | +3.7% | -0.5% |
| Apr 24, 2026 | Oppenheimer resumed coverage on InflaRx with a new price target | -5.1% | +0.8% |
| Apr 9, 2026 | InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor | +8.4% | +0.6% |
Quantisnow market dataNASDAQ
IFRX
InflaRx N.V.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for IFRX
Full IFRX profile on Quantisnow Follow IFRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time